Sigma® Life Science Launches Efflux Transporter Knockout Human Cell
Lines in a Convenient Assay-Ready Format
ST. LOUIS, Nov. 20, 2012 /PRNewswire/
-- Sigma-Aldrich® Corporation (Nasdaq:
SIAL) announced that Sigma Life Science, its innovative biological
products and services business, today launched its
CompoZr® Transporter Knockout human cell lines in a
consumable, assay-ready plate format. The efflux transporter
knockout cell lines allow precise identification of individual
drug-transporter interactions, a critical component for
understanding the safety and efficacy characteristics of drug
candidates. For more information on the CompoZr Transporter
Knockout Assay-Ready Plates,
visit www.sigma.com/transporterko.
"By offering our cell lines in a user-friendly format, these
plates allow customers to avoid handling and maintenance of cell
lines, thus reducing operative costs and time. Meeting the
demands of both the occasional and the high-throughput user, the
new format helps to address many of the unmet needs for preclinical
ADME screening, safety studies, and new regulatory guidelines in
the United States and Europe," said Paul
Brooks, Ph.D., Market Segment Manager at Sigma Life
Science.
The industry's current assays for drug-transporter interactions
use chemical inhibitors, which commonly interact with multiple
transporters simultaneously and thus generate ambiguous
information. The efflux transporter cell lines consist of three
individual knockouts (MDR1, MRP2 and BCRP) and double knockouts
(MDR1:MRP2, MDR1:BCRP and MRP2:BCRP) that are delivered to the
customer in a convenient transwell plate format. These are
ready-to-use in the "gold standard" 21-day monolayer Caco assay for
studying efflux characteristics and so allows flexibility in the
choice and trial of the efflux transporter knockout cell lines to
optimize preclinical screening.
For more information, visit www.sigma.com/transporterko.
Cautionary Statement: The foregoing release contains
forward-looking statements that can be identified by terminology
such as "precise identification," "unambiguous," "easy," or similar
expressions, or by expressed or implied discussions regarding
potential future revenues from products derived there from. You
should not place undue reliance on these statements. Such
forward-looking statements reflect the current views of management
regarding future events, and involve known and unknown risks,
uncertainties and other factors that may cause actual results to be
materially different from any future results, performance or
achievements expressed or implied by such statements. There can be
no guarantee that CompoZr Transporter KO cell lines or related
services will assist the Company to achieve any particular levels
of revenue in the future. In particular, management's expectations
regarding products associated with CompoZr Transporter KO cell
lines or related services could be affected by, among other things,
unexpected regulatory actions or delays or government regulation
generally; the Company's ability to obtain or maintain patent or
other proprietary intellectual property protection; competition in
general; government, industry and general public pricing pressures;
the impact that the foregoing factors could have on the values
attributed to the Company's assets and liabilities as recorded in
its consolidated balance sheet, and other risks and factors
referred to in Sigma-Aldrich's current Form 10-K on file with the
US Securities and Exchange Commission. Should one or more of these
risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially
from those anticipated, believed, estimated or expected.
Sigma-Aldrich is providing the
information in this press release as of this date and does not
undertake any obligation to update any forward-looking statements
contained in this press release as a result of new information,
future events or otherwise.
About Sigma Life Science: Sigma Life Science is a
Sigma-Aldrich business that represents the Company's leadership in
innovative biological products and services for the global life
science market and offers an array of biologically-rich products
and reagents that researchers use in scientific investigation.
Product areas include biomolecules, genomics and functional
genomics, cells and cell-based assays, transgenics, protein assays,
stem cell research, epigenetics and custom
services/oligonucleotides. Sigma Life Science also provides an
extensive range critical bioessentials like biochemicals,
antibiotics, buffers, carbohydrates, enzymes, forensic tools,
hematology and histology, nucleotides, amino acids and their
derivatives, and cell culture media.
About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High
Technology company whose biochemical, organic chemical products,
kits and services are used in scientific research, including
genomic and proteomic research, biotechnology, pharmaceutical
development, the diagnosis of disease and as key components in
pharmaceutical, diagnostics and high technology manufacturing.
Sigma-Aldrich customers include
more than 1.3 million scientists and technologists in life science
companies, university and government institutions, hospitals and
industry. The Company operates in 38 countries and has nearly 9,000
employees whose objective is to provide excellent service
worldwide. Sigma-Aldrich is
committed to accelerating customer success through innovation and
leadership in Life Science and High Technology. For more
information about Sigma-Aldrich, please visit its website at
www.sigma-aldrich.com.
Sigma-Aldrich and Sigma are
trademarks of Sigma-Aldrich Co, LLC registered in the US and other
countries. CompoZr is a registered trademarks of Sigma-Aldrich Co.
LLC.
SOURCE Sigma-Aldrich Corporation